FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800482871> ?p ?o ?g. }

• W2800482871 endingPage "841" @default.
• W2800482871 startingPage "836" @default.
• W2800482871 abstract "The emergence of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) infections requires re-assessment of therapeutic choices. Here we report the efficacy of cefoxitin-based antibiotic therapy for ESBL-E prostatitis. A prospective study including patients with ESBL-E prostatitis resistant to trimethoprim/sulfamethoxazole and fluoroquinolones from January 2014 to March 2016 was conducted. Cefoxitin was administered by continuous infusion for 3 weeks in the case of acute bacterial prostatitis or 6 weeks in the case of chronic bacterial prostatitis (CBP), with intravenous fosfomycin for the first 5 days. Urological investigations were performed to diagnose underlying urinary tract pathology. Clinical and microbiological efficacy were evaluated 3 months (M3) and 6 months (M6) after the end of therapy. A total of 23 patients were included in the study. The median patient age was 74 years (range 48–88 years). Of the 23 infections, 14 (61%) were CBP and 12 (52%) were healthcare-associated infections. The bacteria involved were Escherichia coli in 11 cases, Klebsiella pneumoniae in 10 cases and Klebsiella oxytoca in 2 cases. Clinical cure was observed in 19/23 patients (83%) at M3 and in 17/22 patients (77%) at M6. Urocultures were sterile in 13/23 patients (57%) at M3 and in 9/19 patients (47%) and M6. Urinary colonisation was observed in 6/19 patients (32%) with clinical cure at M3 and 5/14 patients (36%) with clinical cure at M6. No resistance to cefoxitin was detected. Surgical treatment was required for 7/23 patients (30%). In conclusion, cefoxitin-based antibiotic therapy is suitable for difficult-to-treat ESBL-E infections such as prostatitis." @default.
• W2800482871 created "2018-05-17" @default.
• W2800482871 creator A5001635622 @default.
• W2800482871 creator A5012161110 @default.
• W2800482871 creator A5017068888 @default.
• W2800482871 creator A5032564627 @default.
• W2800482871 creator A5057185222 @default.
• W2800482871 creator A5077354106 @default.
• W2800482871 creator A5088285255 @default.
• W2800482871 date "2018-06-01" @default.
• W2800482871 modified "2023-10-01" @default.
• W2800482871 title "Cefoxitin-based antibiotic therapy for extended-spectrum β-lactamase-producing Enterobacteriaceae prostatitis: a prospective pilot study" @default.
• W2800482871 cites W1698613910 @default.
• W2800482871 cites W1838438316 @default.
• W2800482871 cites W1966857852 @default.
• W2800482871 cites W1975295322 @default.
• W2800482871 cites W1982579576 @default.
• W2800482871 cites W1997508973 @default.
• W2800482871 cites W2038179116 @default.
• W2800482871 cites W2080536674 @default.
• W2800482871 cites W2092031489 @default.
• W2800482871 cites W2098752184 @default.
• W2800482871 cites W2101262414 @default.
• W2800482871 cites W2103958498 @default.
• W2800482871 cites W2107334235 @default.
• W2800482871 cites W2149315953 @default.
• W2800482871 cites W2162067003 @default.
• W2800482871 cites W2164120694 @default.
• W2800482871 cites W2275272843 @default.
• W2800482871 cites W2325504095 @default.
• W2800482871 cites W2348468173 @default.
• W2800482871 cites W2394749419 @default.
• W2800482871 cites W2531768967 @default.
• W2800482871 doi "https://doi.org/10.1016/j.ijantimicag.2018.01.008" @default.
• W2800482871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29378342" @default.
• W2800482871 hasPublicationYear "2018" @default.
• W2800482871 type Work @default.
• W2800482871 sameAs 2800482871 @default.
• W2800482871 citedByCount "16" @default.
• W2800482871 countsByYear W28004828712018 @default.
• W2800482871 countsByYear W28004828712019 @default.
• W2800482871 countsByYear W28004828712020 @default.
• W2800482871 countsByYear W28004828712021 @default.
• W2800482871 countsByYear W28004828712022 @default.
• W2800482871 countsByYear W28004828712023 @default.
• W2800482871 crossrefType "journal-article" @default.
• W2800482871 hasAuthorship W2800482871A5001635622 @default.
• W2800482871 hasAuthorship W2800482871A5012161110 @default.
• W2800482871 hasAuthorship W2800482871A5017068888 @default.
• W2800482871 hasAuthorship W2800482871A5032564627 @default.
• W2800482871 hasAuthorship W2800482871A5057185222 @default.
• W2800482871 hasAuthorship W2800482871A5077354106 @default.
• W2800482871 hasAuthorship W2800482871A5088285255 @default.
• W2800482871 hasConcept C104317684 @default.
• W2800482871 hasConcept C121608353 @default.
• W2800482871 hasConcept C126322002 @default.
• W2800482871 hasConcept C141071460 @default.
• W2800482871 hasConcept C188816634 @default.
• W2800482871 hasConcept C2776124114 @default.
• W2800482871 hasConcept C2776235491 @default.
• W2800482871 hasConcept C2777058267 @default.
• W2800482871 hasConcept C2778050735 @default.
• W2800482871 hasConcept C2778897966 @default.
• W2800482871 hasConcept C2779489039 @default.
• W2800482871 hasConcept C2780524745 @default.
• W2800482871 hasConcept C501593827 @default.
• W2800482871 hasConcept C523546767 @default.
• W2800482871 hasConcept C54355233 @default.
• W2800482871 hasConcept C547475151 @default.
• W2800482871 hasConcept C55493867 @default.
• W2800482871 hasConcept C71924100 @default.
• W2800482871 hasConcept C77411442 @default.
• W2800482871 hasConcept C86803240 @default.
• W2800482871 hasConcept C89423630 @default.
• W2800482871 hasConcept C90924648 @default.
• W2800482871 hasConceptScore W2800482871C104317684 @default.
• W2800482871 hasConceptScore W2800482871C121608353 @default.
• W2800482871 hasConceptScore W2800482871C126322002 @default.
• W2800482871 hasConceptScore W2800482871C141071460 @default.
• W2800482871 hasConceptScore W2800482871C188816634 @default.
• W2800482871 hasConceptScore W2800482871C2776124114 @default.
• W2800482871 hasConceptScore W2800482871C2776235491 @default.
• W2800482871 hasConceptScore W2800482871C2777058267 @default.
• W2800482871 hasConceptScore W2800482871C2778050735 @default.
• W2800482871 hasConceptScore W2800482871C2778897966 @default.
• W2800482871 hasConceptScore W2800482871C2779489039 @default.
• W2800482871 hasConceptScore W2800482871C2780524745 @default.
• W2800482871 hasConceptScore W2800482871C501593827 @default.
• W2800482871 hasConceptScore W2800482871C523546767 @default.
• W2800482871 hasConceptScore W2800482871C54355233 @default.
• W2800482871 hasConceptScore W2800482871C547475151 @default.
• W2800482871 hasConceptScore W2800482871C55493867 @default.
• W2800482871 hasConceptScore W2800482871C71924100 @default.
• W2800482871 hasConceptScore W2800482871C77411442 @default.
• W2800482871 hasConceptScore W2800482871C86803240 @default.
• W2800482871 hasConceptScore W2800482871C89423630 @default.
• W2800482871 hasConceptScore W2800482871C90924648 @default.
• W2800482871 hasIssue "6" @default.

• next